Johnson & Johnson (JNJ) To Go Ex-Dividend on August 26th

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Wednesday, July 16th, RTT News reports. Investors of record on Tuesday, August 26th will be paid a dividend of 1.30 per share on Tuesday, September 9th. This represents a $5.20 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date of this dividend is Tuesday, August 26th.

Johnson & Johnson has a payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $11.07 per share next year, which means the company should continue to be able to cover its $5.20 annual dividend with an expected future payout ratio of 47.0%.

Johnson & Johnson Stock Down 1.1%

JNJ stock opened at $163.04 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market capitalization of $392.28 billion, a PE ratio of 17.44, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company has a fifty day moving average of $154.10 and a 200-day moving average of $154.84.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on JNJ shares. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group reissued a “buy” rating and issued a $190.00 target price (up from $180.00) on shares of Johnson & Johnson in a research report on Thursday. Bank of America raised their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $174.11.

Institutional Trading of Johnson & Johnson

A hedge fund recently raised its stake in Johnson & Johnson stock. Brighton Jones LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 13.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 51,876 shares of the company’s stock after acquiring an additional 6,332 shares during the period. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $7,502,000 as of its most recent SEC filing. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.